Comprehensive Management of Molluscum Contagiosum: Assessment of Clinical Associations, Comorbidities, and Management Principles
- PMID: 37636015
- PMCID: PMC10453397
Comprehensive Management of Molluscum Contagiosum: Assessment of Clinical Associations, Comorbidities, and Management Principles
Abstract
Despite its high global prevalence, molluscum contagiosum (MC) is not well understood outside of dermatology. Due to the potential self-limiting nature of MC, a common clinical approach in management is to wait for the papules to resolve spontaneously over several weeks to months, without medical intervention. However, this "watch and wait" approach increases risk of spreading the virus to others, extending the duration of the infection, and emergence of several psychosocial issues (e.g., anxiety, embarrassment, isolation). Molluscum contagiosum can be particularly challenging to treat in immunocompromised patients (e.g., human immunodeficiency virus [HIV], organ transplant recipients). This article reviews diagnostic characteristics and treatment options for MC, as well as associated risk factors and comorbidities. Treatment of immunocompromised individuals, in whom the risks of diffuse MC with persistence and spread are relatively high, is emphasized. The authors highlight the importance of actively treating the MC papules, as opposed to letting the virus "run its course" with no active intervention, with the goals of reducing the risk of spreading infection to others, shortening the duration of infection, and decreasing adverse psychosocial sequelae commonly associated with MC.
Copyright © 2023. Matrix Medical Communications. All rights reserved.
Conflict of interest statement
FINANCIAL DISCLOSURES: Dr. Hebert has received research grants (paid to UTHealth McGovern Medical School) from Verrica, Pfizer, Arcutis, GSK, Ortho Dermatologics, and Galderma, and has received honoraria from Verrica, Pfizer, Galderma, Arcutis, Vine, Almirall, Bristol Myres Squibb, Leo, Vyne, Aslan DSMB: Ortho Dermatologics, GSK, and Sanofi Regeneron. Dr. Del Rosso is a consultant/advisor and investigator for Verrica Pharmaceutical.
Figures
Similar articles
-
Dermoscopic Features of Giant Molluscum Contagiosum in a Patient with Acquired Immunodeficiency Syndrome.Acta Dermatovenerol Croat. 2020 Dec;28(7):233-235. Acta Dermatovenerol Croat. 2020. PMID: 33834996
-
Molluscum Contagiosum: Epidemiology, Considerations, Treatment Options, and Therapeutic Gaps.J Clin Aesthet Dermatol. 2023 Aug;16(8 Suppl 1):S4-S11. J Clin Aesthet Dermatol. 2023. PMID: 37636018 Free PMC article. Review.
-
Extensive Giant Molluscum Contagiosum in a HIV Positive Patient.J Clin Diagn Res. 2015 Nov;9(11):WD01-2. doi: 10.7860/JCDR/2015/15107.6797. Epub 2015 Nov 1. J Clin Diagn Res. 2015. PMID: 26672647 Free PMC article.
-
Molluscum contagiosum of the eyelid: case report in a man receiving methotrexate and literature review of molluscum contagiosum in patients who are immunosuppressed secondary to methotrexate or HIV infection.Dermatol Online J. 2016 Mar 16;22(3):13030/qt8vz669cj. Dermatol Online J. 2016. PMID: 27136625 Review.
-
Beetle juice: a guide for the use of cantharidin in the treatment of molluscum contagiosum.Dermatol Ther. 2013 Nov-Dec;26(6):445-51. doi: 10.1111/dth.12105. Dermatol Ther. 2013. PMID: 24552407 Review.
Cited by
-
Eyelid Lesion of Molluscum contagiosum: A Case Report and Literature Review.Cureus. 2024 Jan 14;16(1):e52272. doi: 10.7759/cureus.52272. eCollection 2024 Jan. Cureus. 2024. PMID: 38357070 Free PMC article.
References
-
- Silverberg N. Pediatric molluscum: an update. Cutis. 2019;104(5):E1–E2. - PubMed
-
- Mathes EF, Frieden IJ. Treatment of molluscum contagiosum with cantharidin: a practical approach. Pediatr Ann. 2010;39(3):124–128, 130. - PubMed
-
- Olsen JR, Gallacher J, Piguet V, Francis NA. Epidemiology of molluscum contagiosum in children: a systematic review. Fam Pract. 2014;31(2):130–136. - PubMed
Publication types
LinkOut - more resources
Full Text Sources